Corbus Pharmaceuticals Holdings, Inc. (FRA:3371)
Germany · Delayed Price · Currency is EUR | Market Cap | 187.45M +83.2% |
| Revenue (ttm) | n/a |
| Net Income | -89.20M |
| EPS | -5.33 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 9.40 |
| Previous Close | 8.88 |
| Day's Range | 9.40 - 9.40 |
| 52-Week Range | 5.80 - 18.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 9, 2026 |
About FRA:3371
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts. [Read more]
News
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the g...
Corbus Pharmaceuticals price target lowered to $33 from $34 at Mizuho
Mizuho lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $33 from $34 and keeps an Outperform rating on the shares. The firm updated the company’s model post the…
Corbus Pharmaceuticals price target lowered to $48 from $52 at Oppenheimer
Oppenheimer lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $48 from $52 and keeps an Outperform rating on the shares following quarterly results and business update. Promising res...
Corbus Pharmaceuticals Holdings Earnings release: Q2 2026
Corbus Pharmaceuticals Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Corbus Pharmaceuticals Holdings Quarterly report: Q2 2026
Corbus Pharmaceuticals Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Corbus reports last patient completes last visit in CANYON-1 trial
Corbus Pharmaceuticals (CRBP) announced the last patient has completed their last clinical visit in the company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1...
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
Dose-finding Phase 1b study (n=240) on track for topline data in September 2026 CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1 ...
Corbus Pharmaceuticals announces FDA clearance to initiate TEMPO-1 trial
Corbus Pharmaceuticals (CRBP) announced that the FDA has cleared the start of the company’s registrational study of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate, in second-line...
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Company expects to initiate enrollment in TEMPO-1 in September 2026 OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patient...
Corbus Pharmaceuticals appoints Viana Nicacio as chief medical officer
Corbus Pharmaceuticals (CRBP) announced the appointment of Leonardo Viana Nicacio as chief medical officer. Prior to joining Corbus, he was the chief medical officer at Protara Therapeutics. Published...
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapi...
Corbus Pharmaceuticals price target lowered to $34 from $44 at Mizuho
Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $34 from $44 and keeps an Outperform rating on the shares. The firm updated its revenue…
Corbus Pharmaceuticals price target lowered to $52 from $54 at Oppenheimer
Oppenheimer lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $52 from $54 and keeps an Outperform rating on the shares. The firm recently hosted a lively investor dinner…
Corbus Pharmaceuticals Holdings Transcript: Jefferies Global Healthcare Conference 2026
Two lead clinical assets are advancing: CRB-701 shows strong efficacy in HPV-positive oropharyngeal and cervical cancers, with pivotal studies aligned with FDA and a significant U.S. market opportunity. CRB-913 obesity data is expected in September, and cash runway extends into 2028.
Corbus Pharmaceuticals Holdings Slides: FY 2026
Corbus Pharmaceuticals Holdings has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.
Corbus Pharmaceuticals Holdings Transcript: KOL event
Panelists highlighted the rising incidence and unmet need in HPV-positive oropharyngeal cancer, emphasizing the promise of Nectin-4 ADCs like CRB-701 for this motivated patient group. Strategic trial design, manageable toxicity, and focused site selection are expected to drive rapid enrollment and strong clinical impact.
Corbus Pharmaceuticals price target lowered to $30 from $38 at Wedbush
Wedbush lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $30 from $38 as the firm refines population assumptions in head and neck squamous cell carcinoma to reflect a…
Corbus Pharmaceuticals share selloff overdone, says Guggenheim
Guggenheim views the weakness today in shares of Corbus Pharmaceuticals (CRBP) as overdone. The company’s CRB-701 data supports the drug’s “strong profile” in head and neck squamous cell carcinoma, th...
Corbus Pharmaceuticals Holdings Transcript: Study update
Updated ASCO data show strong efficacy and safety for CRB-701 in oropharyngeal head and neck and cervical cancers, with a 43% ORR in oropharyngeal and 34% in cervical at the top dose. Ocular toxicity is manageable, and the phase III TEMPO-1 trial will focus on oropharyngeal patients.
Corbus Pharmaceuticals Holdings Press release: Study update
Corbus Pharmaceuticals Holdings issued a press release on May 26, 2026, disclosing material business information to investors.
Corbus Pharmaceuticals Holdings Slides: Study update
Corbus Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Corbus Pharmaceuticals reports updated CRB-701 Phase 1/2 data
Corbus Pharmaceuticals (CRBP) reported updated data from its Phase 1/2 clinical study of CRB-701. The new data demonstrate activity in the second line setting of two solid tumor types that…
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
NORWOOD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today reported updated data from its Phase 1/2 clinical study (NCT0626...
Corbus Pharmaceuticals Holdings Slides: Corporate presentation
Corbus Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Corbus Pharmaceuticals price target raised to $44 from $40 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $44 from $40 and keeps an Outperform rating on the shares. The company surprised by announcing…